NASDAQ:ENTX Entera Bio (ENTX) Stock Forecast, Price & News $0.65 -0.06 (-8.44%) (As of 09/25/2023 ET) Add Compare Share Share Today's Range$0.57▼$0.7050-Day Range$0.59▼$0.8752-Week Range$0.47▼$1.48Volume47,371 shsAverage Volume109,878 shsMarket Capitalization$18.75 millionP/E RatioN/ADividend YieldN/APrice Target$10.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Entera Bio MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,436.1% Upside$10.00 Price TargetShort InterestHealthy0.12% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$24,000 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($0.33) to ($0.76) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.75 out of 5 starsMedical Sector788th out of 962 stocksBiological Products, Except Diagnostic Industry126th out of 161 stocks 3.5 Analyst's Opinion Consensus RatingEntera Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.00, Entera Bio has a forecasted upside of 1,436.1% from its current price of $0.65.Amount of Analyst CoverageEntera Bio has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.12% of the float of Entera Bio has been sold short.Short Interest Ratio / Days to CoverEntera Bio has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Entera Bio has recently increased by 24.88%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldEntera Bio does not currently pay a dividend.Dividend GrowthEntera Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ENTX. Previous Next 0.6 News and Social Media Coverage Search Interest4 people have searched for ENTX on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Entera Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Entera Bio insiders have bought more of their company's stock than they have sold. Specifically, they have bought $24,000.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 8.90% of the stock of Entera Bio is held by insiders.Percentage Held by InstitutionsOnly 8.92% of the stock of Entera Bio is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Entera Bio are expected to decrease in the coming year, from ($0.33) to ($0.76) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Entera Bio is -1.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Entera Bio is -1.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEntera Bio has a P/B Ratio of 1.59. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Entera Bio (NASDAQ:ENTX) StockEntera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and hGh for the GH deficiency. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.Read More ENTX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ENTX Stock News HeadlinesSeptember 13, 2023 | finance.yahoo.comOPKO Health (OPK) Ties Up for Oral Peptide Tablet FormulationsSeptember 5, 2023 | finance.yahoo.comEntera Bio to Participate in Upcoming Investor ConferencesSeptember 26, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.August 16, 2023 | finance.yahoo.comEntera Bio to Present Two Abstracts on its First-in-Class, Once Daily Oral hPTH(1-34) Peptide Tablets (EB613) for the Treatment of Post-Menopausal Women at High Risk of Fracture at the American Society for Bone and Mineral Research (ASBMR) Annual MeetingAugust 12, 2023 | finanznachrichten.deEntera Bio Ltd.: Entera Bio Announces Q2 2023 Financial Results and Corporate UpdatesAugust 11, 2023 | finance.yahoo.comEntera Bio Announces Q2 2023 Financial Results and Corporate UpdatesJune 7, 2023 | finanznachrichten.deEntera Bio Ltd.: Entera Bio Adds Sanofi Commercial Leader, Haya Taitel to its Board of DirectorsJune 7, 2023 | technews.tmcnet.comEntera Bio Adds Sanofi Commercial Leader, Haya Taitel to its Board of DirectorsSeptember 26, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.May 7, 2023 | finance.yahoo.comEntera Bio First Quarter 2023 Earnings: US$0.076 loss per share (vs US$0.13 loss in 1Q 2022)May 6, 2023 | finanznachrichten.deEntera Bio Ltd.: Entera Bio Announces Q1 2023 Financial Results and Corporate UpdatesMay 5, 2023 | finance.yahoo.comEntera Bio Ltd. (ENTX) Reports Q1 Loss, Misses Revenue EstimatesMay 5, 2023 | msn.comEntera Bio: Q1 Earnings InsightsMay 5, 2023 | finance.yahoo.comEntera Bio Announces Q1 2023 Financial Results and Corporate UpdatesMay 3, 2023 | technews.tmcnet.comEntera's Oral Delivery of GLP-2 Pre-Clinical Data to be Published in Peer Reviewed, International Journal of Peptide Research and TherapeuticsMay 3, 2023 | finance.yahoo.comEntera’s Oral Delivery of GLP-2 Pre-Clinical Data to be Published in Peer Reviewed, International Journal of Peptide Research and TherapeuticsApril 27, 2023 | marketwatch.comMenopause Luminary, Dr. Steven R. Goldstein, Joins Entera's Clinical and Scientific Advisory BoardApril 26, 2023 | finance.yahoo.comMenopause Luminary, Dr. Steven R. Goldstein, Joins Entera’s Clinical and Scientific Advisory BoardApril 4, 2023 | msn.comHC Wainwright & Co. Reiterates Entera Bio (ENTX) Buy RecommendationApril 4, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Their Buy Rating for Entera Bio (ENTX)April 3, 2023 | finance.yahoo.comEntera Bio Provides Guidance from FDA Type D Meeting Related to EB613 Pivotal ProgramMarch 31, 2023 | finance.yahoo.comEntera Bio Ltd. (ENTX) Reports Q4 Loss, Lags Revenue EstimatesMarch 31, 2023 | finance.yahoo.comEntera Bio Provides 2022 Corporate Milestones and Financial Results for the Year Ended December 31, 2022March 23, 2023 | finance.yahoo.comEntera Bio Regains Compliance with Nasdaq Listing RequirementsMarch 10, 2023 | finance.yahoo.comWill Entera Bio (NASDAQ:ENTX) Spend Its Cash Wisely?February 20, 2023 | finance.yahoo.comEntera Bio (ENTX) to Report Q4 Earnings: What's in the Cards?February 15, 2023 | finance.yahoo.comEntera Bio Announces FDA’s Acceptance of a Type D Meeting Review to Affirm Design of the Pivotal, Phase 3 Protocol for EB613 PTH Mini Tablets, as the First Oral Osteoanabolic Treatment of Post-Menopausal OsteoporosisSee More Headlines Receive ENTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Entera Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address ENTX Company Calendar Last Earnings8/11/2023Today9/25/2023Next Earnings (Estimated)11/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ENTX CUSIPN/A CIK1638097 Webwww.enterabio.com Phone(722) 532-7151FaxN/AEmployees19Year FoundedN/APrice Target and Rating Average Stock Price Forecast$10.00 High Stock Price Forecast$10.00 Low Stock Price Forecast$10.00 Forecasted Upside/Downside+1,436.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-13,070,000.00 Net Margins-9,754.48% Pretax Margin-47,586.36% Return on Equity-95.70% Return on Assets-83.73% Debt Debt-to-Equity RatioN/A Current Ratio5.26 Quick Ratio5.26 Sales & Book Value Annual Sales$130,000.00 Price / Sales144.22 Cash FlowN/A Price / Cash FlowN/A Book Value$0.41 per share Price / Book1.59Miscellaneous Outstanding Shares28,800,000Free Float26,240,000Market Cap$18.75 million OptionableNot Optionable Beta1.84 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMs. Miranda J. Toledano M.B.A. (Age 46)CEO & Director Comp: $412.5kDr. Hillel Galitzer M.B.A. (Age 45)Ph.D., Chief Operating Officer Comp: $387kMs. Dana Yaacov-Garbeli CPA (Age 40)Chief Financial Officer Dr. Arthur C. Santora II (Age 72)M.D., Ph.D., Chief Medical Officer Key CompetitorsMicrobot MedicalNASDAQ:MBOTAcorda TherapeuticsNASDAQ:ACORProtara TherapeuticsNASDAQ:TARAHarpoon TherapeuticsNASDAQ:HARPFreeline TherapeuticsNASDAQ:FRLNView All CompetitorsInsiders & InstitutionsSean EllisBought 40,000 shares on 8/21/2023Total: $24,000.00 ($0.60/share)Simplex Trading LLCBought 100 shares on 8/4/2023Ownership: 0.000%Miranda Jayne ToledanoBought 30,000 shares on 4/4/2023Total: $30,300.00 ($1.01/share)Sean EllisBought 30,000 shares on 11/11/2022Total: $15,900.00 ($0.53/share)Miranda Jayne ToledanoBought 50,000 shares on 11/11/2022Total: $26,500.00 ($0.53/share)View All Insider TransactionsView All Institutional Transactions ENTX Stock - Frequently Asked Questions Should I buy or sell Entera Bio stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Entera Bio in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ENTX shares. View ENTX analyst ratings or view top-rated stocks. What is Entera Bio's stock price forecast for 2023? 1 Wall Street analysts have issued 12 month target prices for Entera Bio's shares. Their ENTX share price forecasts range from $10.00 to $10.00. On average, they predict the company's stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 1,436.1% from the stock's current price. View analysts price targets for ENTX or view top-rated stocks among Wall Street analysts. How have ENTX shares performed in 2023? Entera Bio's stock was trading at $0.73 on January 1st, 2023. Since then, ENTX shares have decreased by 10.8% and is now trading at $0.6510. View the best growth stocks for 2023 here. Are investors shorting Entera Bio? Entera Bio saw a increase in short interest in August. As of August 31st, there was short interest totaling 26,600 shares, an increase of 24.9% from the August 15th total of 21,300 shares. Based on an average trading volume of 32,100 shares, the short-interest ratio is presently 0.8 days. Currently, 0.1% of the company's stock are short sold. View Entera Bio's Short Interest. When is Entera Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023. View our ENTX earnings forecast. How were Entera Bio's earnings last quarter? Entera Bio Ltd. (NASDAQ:ENTX) posted its quarterly earnings results on Friday, August, 11th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by $0.01. Entera Bio had a negative trailing twelve-month return on equity of 95.70% and a negative net margin of 9,754.48%. What other stocks do shareholders of Entera Bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other Entera Bio investors own include Fulcrum Therapeutics (FULC), Cara Therapeutics (CARA), Gilead Sciences (GILD), Supernus Pharmaceuticals (SUPN), VIVUS (VVUS), Vaxart (VXRT), AbbVie (ABBV), Acasti Pharma (ACST) and Allena Pharmaceuticals (ALNA). When did Entera Bio IPO? (ENTX) raised $11 million in an IPO on Thursday, June 28th 2018. The company issued 1,400,000 shares at $8.00 per share. Maxim Group acted as the underwriter for the IPO and Joseph Gunnar was co-manager. What is Entera Bio's stock symbol? Entera Bio trades on the NASDAQ under the ticker symbol "ENTX." Who are Entera Bio's major shareholders? Entera Bio's stock is owned by many different retail and institutional investors. Top institutional shareholders include Simplex Trading LLC (0.00%). Insiders that own company stock include Miranda Jayne Toledano, Ramesh Ratan, Ron Mayron, Sean Ellis and Yonatan Malca. View institutional ownership trends. How do I buy shares of Entera Bio? Shares of ENTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Entera Bio's stock price today? One share of ENTX stock can currently be purchased for approximately $0.65. How much money does Entera Bio make? Entera Bio (NASDAQ:ENTX) has a market capitalization of $18.75 million and generates $130,000.00 in revenue each year. The company earns $-13,070,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis. How can I contact Entera Bio? Entera Bio's mailing address is FIFTH FLOOR KIRYAT HADASSAH MINRAV BUILDING, JERUSALEM L3, 9112002. The official website for the company is www.enterabio.com. The company can be reached via phone at (722) 532-7151 or via email at investorrelations@enterabio.com. This page (NASDAQ:ENTX) was last updated on 9/26/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entera Bio Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.